Latest Articles

Publication Date
All News Scientific
Leveraging epigenetic aberrations in the pathogenesis of endometriosis: From DNA methylation to non-coding RNAs - Frontiers

Leveraging epigenetic aberrations in the pathogenesis of endometriosis: From DNA methylation to non-coding RNAs Frontiers

Published: June 9, 2025, 4:59 p.m.
Read Full Article
Game-changing new tests to spot endometriosis early and spare women years of agony - Daily Mail

Game-changing new tests to spot endometriosis early and spare women years of agony Daily Mail

Published: June 9, 2025, 3:31 p.m.
Read Full Article
Game-changing tests to spot endometriosis early stop years of agony - Daily Mail

Game-changing tests to spot endometriosis early stop years of agony Daily Mail

Published: June 9, 2025, 3:31 p.m.
Read Full Article
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - HealthDay

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer HealthDay

Published: June 9, 2025, 2:50 p.m.
Read Full Article
AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News - GuruFocus

AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:46 p.m.
Read Full Article
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace

Published: June 9, 2025, 12:43 p.m.
Read Full Article
Actor Sa Gang left a recent update after endometriosis surgery.On the afternoon of the 9th, Sagang o.. - 매일경제

Actor Sa Gang left a recent update after endometriosis surgery.On the afternoon of the 9th, Sagang o.. 매일경제

Published: June 9, 2025, 12:39 p.m.
Read Full Article
EZH2 Promotes Endometriosis Progression through Estrogen Receptor and TNFα Expression - Frontiers

EZH2 Promotes Endometriosis Progression through Estrogen Receptor and TNFα Expression Frontiers

Published: June 9, 2025, 12:32 p.m.
Read Full Article
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:18 p.m.
Read Full Article
Phase 3 Trial Launches ENHERTU as First-Line Endometrial Cancer Treatment | CGEN Stock News - Stock Titan

Phase 3 Trial Launches ENHERTU as First-Line Endometrial Cancer Treatment | CGEN Stock News Stock Titan

Published: June 9, 2025, noon
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!